Astell roll out latest colour touchscreen controllers for new autoclave range
16 December 2016 | By Astell Scientific
Astell Scientific is introducing its latest version controller as standard fitment to all models in the range...
List view / Grid view
News
Yusen Logistics Russia LLC launches air import consolidation services in Moscow and St. Petersburg
Yusen Logistics has launched air import consolidation services at Moscow’s Sheremetyevo airport (SVO1/SVO2) and Domodedovo airport (DME), as well as Pulkovo airport (LED) in St. Petersburg.
Steven Brimble appointed as new Quality Manager for Cherwell
15 December 2016 | By Cherwell Laboratories
Company continues its emphasis on delivering quality environmental monitoring and cleanroom microbiology solutions...
Sanitary sifter improves purity of dietary supplements at Enzymatic Therapy
Enzymatic Therapy, a leading manufacturer of dietary supplements and natural medicines chose to build its own FDA-approved manufacturing facility, with the primary goal of improving product quality, streamlining production, and ultimately ramping up sales growth.
New look autoclave range from Astell Scientific
15 December 2016 | By Astell Scientific
Astell Scientific is pleased to announce the launch of a new and improved range of autoclaves...
Multi-national pharma company reduces raw materials QC costs by 90% with through-container ID testing
14 December 2016 | By Cobalt Light Systems
A case study from Astellas Pharma Tech Co. Ltd., Japan, describes how Cobalt’s RapID verifies the ID of raw materials through unopened paper and polyethylene sacks...
Yusen Logistics expands its European network with launch in Switzerland
Global logistics service provider Yusen Logistics is continuing to grow its network and will open its first location in Switzerland on 1st January 2017.
Scottish Medicines Consortium approves Sanofi prostate cancer drug
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Prostate cancer can become resistant to hormone therapy and continue to grow despite treatment. Jevtana (cabazitaxel) is the only remaining chemotherapy...
Novartis’ macular degeneration Phase III trial did not meet endpoint
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Novartis' two pivotal Phase III clinical studies did not meet their primary endpoints to treatment of neovascular age-related macular degeneration...
Biocartis launches second liquid biopsy assay
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Biocartis launched its second liquid biopsy assay, the Idylla ctKRAS Mutation Assay, which was developed in partnership with Merck...
Deloitte and VTC Group form new healthcare technology partnership
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The VTC Group is pleased to announce a partnership with Deloitte, to create a Deloitte Healthcare Virtual Technology Cluster...
EMA to review Sanofi and Regeneron’s dermatitis drug application
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
Success for EIP Pharma’s two Phase 2a Alzheimer’s Disease clinical trials
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The results of two recently completed Phase 2a clinical trials that demonstrated significant Alzheimer's disease relevant pharmacological activity...
Novartis’ SMS for Life 2.0 to improve access to medicines in Nigeria
12 December 2016 | By Niamh Louise Marriott, Digital Editor
The new and enhanced SMS for Life 2.0 program will now use smartphone and tablet computers to address key operational challenges at peripheral healthcare...
Novartis’ NSCLC study shows 16.6 month progression-free survival
12 December 2016 | By Niamh Louise Marriott, Digital Editor
Patients with ALK+ advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to placebo...
